Allergy

Despite an FDA CRL over usability, trial data suggest the needle-free epinephrine film rivals autoinjectors in speed and absorption, with promise for real-world readiness.

Vaginal delivery, exclusive breastfeeding, and early sibling exposure strongly predicted colonization with bifidobacteria that suppress IgE responses in a recent study.

Longitudinal data identify aromatic lactate–producing bifidobacteria and the metabolite 4-hydroxy-phenyllactate as key factors in early immune tolerance.

FDA clears pediatric HAE oral therapy as intranasal epinephrine and heat-treated peanut/egg OIT studies point to safer allergy care.

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

The CRL cited deficiencies limited to packaging and administration, with resubmission expected as early as Q3 2026.

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 data and updated asthma guidelines, in this week’s essential news roundup.

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.

Interim phase 2 results show NS002 delivered faster absorption and greater early epinephrine exposure than EpiPen, with comparable safety and tolerability.

Upton discusses an open-label trial showing a 30 mg per nut very low-dose oral immunotherapy strategy increased multi-nut tolerance and remained safe in children.

Reduced IgE binding and blunted basophil activation in response to Gal d 1 and Gal d 2 suggest that heat-treated egg proteins could improve the safety of OIT for egg-allergic patients.

Berotralstat becomes the first once-daily oral prophylactic option for long-term prevention of hereditary angioedema in children aged 2–11 years.

Analysis of > 9,000 FDA reports highlights previously unrecognized adverse events, including myocardial stunning, nerve damage, and real-world drug ineffectiveness.

An 18-month study of children with up to 5 nut allergies found that a 30-mg per-nut maintenance dose significantly improved tolerated doses without serious adverse events.

A study found tahini was associated with lower reaction thresholds and higher anaphylaxis rates than whole seeds, suggesting it may better reflect true sesame allergy risk.

A study links caregiver beliefs, mental health challenges, multiple allergens, and prior anaphylaxis to worse food allergy–related quality of life in pediatric patients.

Q4 2025 brought key FDA approvals and phase 3 advances in HAE, peanut allergy, multi-allergen immunotherapy, and allergic fungal rhinosinusitis.

December highlights: FDA approval of berotralstat for pediatric HAE, phase 3 RAPIDe-3 results, and allergy field spotlights in our This Year in Medicine series.

Nurse practitioners play a key role in allergy and asthma care using specific IgE blood testing to identify triggers, improve outcomes, and ease shortages.

Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.

Study finds comparable IgE reductions with heated milk and conventional desensitization, but heated milk linked to higher anaphylaxis risk in children with cow’s milk allergy.

DBV Technologies announced that the phase 3 VITESSE trial on VIASKIN® Peanut patch for peanut-allergic children met its primary endpoint.